Protara Therapeutics Income Statement (2013-2026) | TARA

1Y3Y5Y7Y10YAll
Download Data
Income Statement Sep2013 Dec2013 Mar2014 Jun2014 Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter)
Operating items
Amortization - Intangibles (Quarter)
-0.35M-0.27M-0.11M0.08M0.13M0.13M0.11M0.07M0.01M0.44M0.29M0.17M0.39M0.44M0.32M0.18M
Research & Development (Quarter)
5.89M4.09M4.07M5.27M3.08M3.47M4.99M5.14M7.25M6.22M6.38M7.75M6.39M8.07M9.50M9.15M10.77M9.59M13.12M13.56M
Wages, Salaries and Other (Quarter)
Selling, General & Administrative (Quarter)
6.91M6.74M6.22M5.61M5.62M4.51M5.00M4.59M4.89M4.48M4.66M4.10M4.27M4.26M4.81M4.98M5.82M5.17M5.96M6.07M
Other Operating Expenses (Quarter)
29.52M
Operating Expenses (Quarter)
12.79M10.83M10.29M10.87M8.71M7.97M39.51M9.73M12.14M10.70M11.04M11.85M10.66M12.33M14.31M14.12M16.59M14.76M19.08M19.63M
Operating Income (Quarter)
-12.79M-10.83M-10.29M-10.87M-8.71M-7.97M-39.51M-9.73M-12.14M-10.70M-11.04M-11.85M-10.66M-12.33M-14.31M-14.12M-16.59M-14.76M-19.08M-19.63M
EBIT (Quarter)
-12.79M-10.83M-10.29M-10.87M-8.71M-7.97M-39.51M-9.73M-12.14M-10.70M-11.04M-11.85M-10.66M-12.33M-14.31M-14.12M-16.59M-14.76M-19.08M-19.63M
Non-operating items
Interest & Investment Income (Quarter)
0.01M0.05M0.06M0.12M0.51M0.28M0.63M0.60M0.85M0.84M0.82M0.76M1.13M1.11M0.31M1.55M1.22M1.50M0.17M1.66M
Other Non Operating Income (Quarter)
0.48M0.25M
Non Operating Income (Quarter)
0.01M0.05M0.06M0.12M0.17M0.28M0.54M0.69M0.85M0.84M0.82M0.76M1.15M1.11M1.54M2.21M1.63M1.50M1.77M1.85M
Net income details
EBT (Quarter)
-12.78M-10.78M-10.23M-10.76M-8.19M-7.69M-38.88M-9.13M-11.29M-9.86M-10.22M-11.10M-9.53M-11.22M-14.00M-12.57M-15.36M-13.26M-18.91M-17.97M
Profit After Tax (Quarter)
-12.78M-10.78M-10.23M-10.76M-8.54M-7.69M-38.97M-9.04M-11.29M-9.86M-10.22M-11.10M-9.51M-11.22M-12.77M-11.91M-14.96M-13.26M-17.31M-17.78M
Income from Continuing Operations (Quarter)
-12.78M-10.78M-10.23M-10.76M-8.19M-7.69M-38.88M-9.13M-11.29M-9.86M-10.22M-11.10M-9.53M-11.22M-14.00M-12.57M-15.36M-13.26M-18.91M-17.97M
Consolidated Net Income (Quarter)
-12.78M-10.78M-10.23M-10.76M-8.19M-7.69M-38.88M-9.13M-11.29M-9.86M-10.22M-11.10M-9.53M-11.22M-14.00M-12.57M-15.36M-13.26M-18.91M-17.97M
Income towards Parent Company (Quarter)
-12.78M-10.78M-10.23M-10.76M-8.19M-7.69M-38.88M-9.13M-11.29M-9.86M-10.22M-11.10M-9.53M-11.22M-14.00M-12.57M-15.36M-13.26M-18.91M-17.97M
Preferred Dividend Payments (Quarter)
Net Income towards Common Stockholders (Quarter)
-12.78M10.60M10.23M10.76M-30.05M-7.69M-38.97M9.04M-29.38M-9.86M-10.22M-11.10M-9.53M-11.22M-14.00M-12.57M-15.36M-13.26M-18.91M-17.97M
Additional items
EPS (Basic) (Quarter)
-1.14-0.96-0.91-0.96-0.76-0.68-3.46-0.80-1.00-0.87-0.90-0.97-0.45-0.50-0.43-0.29-0.35-0.31-0.38-0.31
EPS (Weighted Average and Diluted) (Quarter)
-1.14-0.96-0.91-0.96-0.76-0.68-3.46-0.80-1.00-0.87-0.90-0.97-0.45-0.50-0.43-0.29-0.35-0.31-0.38-0.31
Shares Outstanding (Weighted Average) (Quarter)
11.23M11.24M11.23M11.25M11.26M11.27M11.26M11.30M11.31M11.32M11.33M11.42M16.33M18.34M20.59M40.71M42.27M41.76M13.52M57.54M
Shares Outstanding (Diluted Average) (Quarter)
11.23M11.24M11.23M11.25M11.25M11.26M11.26M11.30M11.31M11.32M11.33M11.42M21.23M18.34M20.59M40.71M41.49M42.27M42.84M57.54M
EBITDA (Quarter)
-12.72M-10.71M-10.40M-11.49M-8.72M-7.70M-38.52M-8.83M-11.16M-9.69M-10.09M-11.06M-9.51M-11.19M-12.80M-11.83M-14.97M-13.19M-17.36M-18.24M
Interest Expenses (Quarter)
Shares Outstanding (Quarter)
11.23M11.24M0.01M11.25M0.01M0.01M0.01M0.01M11.31M0.01M0.01M0.01M0.01M20.63M0.01M38.58M0.01M38.59M53.59M55.06M